|glycoprotein hormones, alpha polypeptide|
|Locus||Chr. 6 q14-q21|
|follicle stimulating hormone, beta polypeptide|
|Locus||Chr. 11 p13|
Follicle-stimulating hormone (FSH) is a glycoprotein hormone found in humans and other animals. It is synthesized and secreted by gonadotrophs of the anterior pituitary gland, and regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and luteinizing hormone (LH) act synergistically in reproduction.
FSH is a 35.5 kDa glycoprotein heterodimer, consisting of two polypeptide units, alpha and beta. Its structure is similar to those of luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG). The alpha subunits of the glycoproteins LH, FSH, TSH, and hCG are virtually identical and consist of about 96 amino acids, while the beta subunits vary. Both subunits are required for biological activity. FSH has a beta subunit of 111 amino acids (FSH β), which confers its specific biologic action, and is responsible for interaction with the follicle-stimulating hormone receptor. The sugar portion of the hormone is covalently bonded to asparagine, and is composed of N-acetylgalactosamine, mannose, N-acetylglucosamine, galactose, and sialic acid, the last one being critical for its biological half-life of 3–4 years.
The gene for the alpha subunit is located at cytogenetic location 6q14.3. It is expressed in different cell types, most notably the basophils of the anterior pituitary. The gene for the FSH beta subunit is located on chromosome 11p13, and is expressed in gonadotropes of the pituitary cells, controlled by GnRH, inhibited by inhibin, and enhanced by activin.
FSH regulates the development, growth, pubertal maturation and reproductive processes of the human body.
- In both males and females, FSH stimulates the maturation of germ cells.
- In males, FSH induces Sertoli cells to secrete androgen-binding proteins (ABPs), regulated by inhibin's negative feedback mechanism on the anterior pituitary.
- In females, FSH initiates follicular growth, specifically affecting granulosa cells. With the concomitant rise in inhibin B, FSH levels then decline in the late follicular phase. This seems to be critical in selecting only the most advanced follicle to proceed to ovulation. At the end of the luteal phase, there is a slight rise in FSH that seems to be of importance to start the next ovulatory cycle.
Control of FSH release from the pituitary gland is unknown. Low frequency gonadotropin-releasing hormone (GnRH) pulses increase FSH mRNA levels in the rat, but is not directly correlated with an increase in circulating FSH. GnRH has been shown to play an important role in the secretion of FSH, with hypothalamic-pituitary disconnection leading to a cessation of FSH. GnRH administration leads to a return of FSH secretion. FSH is subject to oestrogen feed-back from the gonads via the hypothalamic pituitary gonadal axis.
Effects in females
FSH stimulates the growth and recruitment of immature ovarian follicles in the ovary. In early (small) antral follicles, FSH is the major survival factor that rescues the small antral follicles (2–5 mm in diameter for humans) from apoptosis (programmed death of the somatic cells of the follicle and oocyte). In the luteal-follicle phase transition period the serum levels of progesterone and estrogen (primarily estradiol) decrease and no longer suppress the release of FSH, consequently FSH peaks at about day three (day one is the first day of menstrual flow). The cohort of small antral follicles is normally sufficiently in number to produce enough Inhibin B to lower FSH serum levels.
In addition, there is evidence that gonadotrophin surge-attenuating factor produced by small follicles during the first half of the follicle phase also exerts a negative feedback on pulsatile luteinizing hormone (LH) secretion amplitude, thus allowing a more favorable environment for follicle growth and preventing premature luteinization.
(As a woman nears perimenopause, the number of small antral follicles recruited in each cycle diminishes and consequently insufficient Inhibin B is produced to fully lower FSH and the serum level of FSH begins to rise. Eventually the FSH level becomes so high that downregulation of FSH receptors occurs and by postmenopause any remaining small secondary follicles no longer have FSH nor LH receptors.)
When the follicle matures and reaches 8–10 mm in diameter it starts to secrete significant amounts of estradiol. Normally in humans only one follicle becomes dominant and survives to grow to 18–30 mm in size and ovulate, the remaining follicles in the cohort undergo atresia. The sharp increase in estradiol production by the dominant follicle (possibly along with a decrease in gonadotrophin surge-attenuating factor) cause a positive effect on the hypothalamus and pituitary and rapid GnRH pulses occur and an LH surge results.
The decrease in serum FSH level causes the smaller follicles in the current cohort to undergo atresia as they lack sufficient sensitivity to FSH to survive. Occasionally two follicles reach the 10 mm stage at the same time by chance and as both are equally sensitive to FSH both survive and grow in the low FSH environment and thus two ovulations can occur in one cycle possibly leading to non identical (dizygotic) twins.
Effects in males
FSH enhances the production of androgen-binding protein by the Sertoli cells of the testes by binding to FSH receptors on their basolateral membranes, and is critical for the initiation of spermatogenesis.
Follicle stimulating hormone is typically measured in the early follicular phase of the menstrual cycle, typically day three to five, counted from last menstruation. At this time, the levels of estradiol (E2) and progesterone are at the lowest point of the menstrual cycle. FSH levels in this time is often called basal FSH levels, to distinguish from the increased levels when approaching ovulation.
FSH is measured in International Units (IU). For Human Urinary FSH, one IU is defined as the amount of FSH that has an activity corresponding to 0.11388 mg of pure Human Urinary FSH. For recombinant FSH, one IU corresponds to approximately 0.065 to 0.075 µg of a "fill-by-mass" product.
|This section does not cite any references or sources. (September 2010)|
High FSH levels
The most common reason for high serum FSH concentration is in a female who is undergoing or has recently undergone menopause. High levels of Follicle-Stimulating Hormone indicate that the normal restricting feedback from the gonad is absent, leading to an unrestricted pituitary FSH production.
If high FSH levels occur during the reproductive years, it is abnormal. Conditions with high FSH levels include:
- Premature menopause also known as Premature Ovarian Failure
- Poor ovarian reserve also known as Premature Ovarian Aging
- Gonadal dysgenesis, Turner syndrome
- Swyer syndrome
- Certain forms of CAH
- Testicular failure.
- Klinefelter syndrome
- Systemic Lupus Erythematosus also known as Lupus 
Most of these conditions are associated with subfertility and/or infertility. Therefore high FSH levels are an indication of subfertility and/or infertility.
Low FSH levels
Diminished secretion of FSH can result in failure of gonadal function (hypogonadism). This condition is typically manifested in males as failure in production of normal numbers of sperm. In females, cessation of reproductive cycles is commonly observed. Conditions with very low FSH secretions are:
- Polycystic Ovarian Syndrome
- Polycystic Ovarian Syndrome + Obesity + Hirsutism + Infertility
- Kallmann syndrome
- Hypothalamic suppression
- Gonadotropin deficiency
- Gonadal suppression therapy
Use as therapy
FSH is available mixed with LH activity in various menotropins including more purified forms of urinary gonadotropins such as Menopur, as well as without LH activity as recombinant FSH (Gonapure, Gonal F, Follistim, Follitropin alpha).
Potential role in vascularization of solid tumors
Elevated FSH receptor levels have been detected in the endothelia of tumor vasculature in a very wide range of solid tumors. FSH binding is thought to upregulate neovascularization via at least two mechanisms – one in the VEGF pathway, and the other VEGF independent – related to the development of umbilical vasculature when physiological. This presents possible use of FSH and FSH-receptor antagonists as an anti tumor angiogenesis therapy (cf. avastin for current anti-VEGF approaches).
- "Follicle-Stimulating Hormone".
- Pierce, J G; Parsons, T F (June 1981). "Glycoprotein Hormones: Structure and Function". Annual Review of Biochemistry 50 (1): 465–495. doi:10.1146/annurev.bi.50.070181.002341. PMID 6267989. Retrieved 9 December 2014.
- Jiang X, Liu H, Chen X, Chen PH, Fischer D, Sriraman V, Yu HN, Arkinstall S, He X (July 2012). "Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor". Proc Natl Acad Sci U S A 109 (31): 12491–6. doi:10.1073/pnas.1206643109. PMID 22802634.
- Fowler PA, Sorsa-Leslie T, Harris W, Mason HD (December 2003). "Ovarian gonadotrophin surge-attenuating factor (GnSAF): where are we after 20 years of research?". Reproduction 126 (6): 689–99. doi:10.1530/rep.0.1260689. PMID 14748688.
- Vihko KK (May 1996). "Gonadotropins and ovarian gonadotropin receptors during the perimenopausal transition period". Maturitas 23 (Supplement): S19–22. PMID 8865134.
- Dickerson LM, Shrader SP, Diaz VA (2008). "Chapter 8: Contraception". In Wells BG, DiPiro JT, Talbert RL, Yee GC, Matzke GR. Pharmacotherapy: a pathophysiologic approach. McGraw-Hill Medical. pp. 1313–28. ISBN 0-07-147899-X.
- Boulpaep EL, Boron WF (2005). Medical physiology: a cellular and molecular approach. St. Louis, Mo: Elsevier Saunders. p. 1125. ISBN 1-4160-2328-3.
- World Health Organization Technical Report Series N0. 565. WHO Expert Committee on Biological Standardization. Twenty-sixth Report. World Health Organization. Geneva. 1975
- "Gonadotropin preparations: Past, present, and future perspectives". Fertility and Sterility 90 (5 Suppl): S13–20. 2008. doi:10.1016/j.fertnstert.2008.08.031. PMID 19007609.
- Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N (October 2010). "Expression of follicle-stimulating hormone receptor in tumor blood vessels". N. Engl. J. Med. 363 (17): 1621–30. doi:10.1056/NEJMoa1001283. PMID 20961245.
|Wikimedia Commons has media related to Follicle-stimulating hormone.|
- FSH - Lab Tests Online